Visceral leishmaniasis in a patient taking adalimumab for rheumatoid arthritis

Medical Journal of Australia

Volumn 198, Issue 6, 2013, Pages 331-333

  Berry, Catherine E ^a   Tsai, Jeffrey ^a   Tierney, Alexander ^a   Pickles, Robert ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMPHOTERICIN; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FERRITIN; HEMOGLOBIN; IMMUNOGLOBULIN; METHOTREXATE;

ABNORMAL LABORATORY RESULT; ADULT; ARTHROPOD DISEASE; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; DIFFERENTIAL DIAGNOSIS; DIZZINESS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; LEISHMANIA INFANTUM; LUNG INFILTRATE; LUNG NODULE; MALAISE; MEDICAL HISTORY; OPPORTUNISTIC INFECTION; PANCYTOPENIA; POSITRON EMISSION TOMOGRAPHY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SPLENECTOMY; SPLENOMEGALY; SWEATING; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LEISHMANIASIS, VISCERAL;

EID: 84876241563     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja12.11003     Document Type: Article

References (11)

1. Magill AJ. Leishmania species: visceral (kala-azar), cutaneous, and mucosal leishmaniasis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Vol 2. Philadelphia: Churchill Livingstone/Elsevier, 2010: 3463-3480.
2. Bogdan C. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012; 71 Suppl 2: i60-i66. doi: 10.1136/annrheumdis-2011-200596.
3. Hamilton A, Kelleher A, Marriott D. A case of severe visceral leishmaniasis resulting from travel to Greece. BMJ Case Rep 2009; 2009 pii: bcr06.2009.2036. doi: 10.1136/bcr.06.2009.2036.
4. Khan A, Coakley A, Cosgrove C, Lockwood D. Let off the leash: kala-azar following the use of tumour necrosis factor antibodies. BMJ Case Rep 2010; 2010 pii: bcr0420102878. doi: 10.1136/bcr.04.2010.2878.
5. Cascio A, Iaria M, Iaria C. Leishmaniasis and biologic therapies for rheumatologic diseases. Semin Arthritis Rheum 2010; 40: e3-e5.
6. Erre GL, Mesina P, Tonelli N, Passiu G. Visceral leishmaniasis among immunosuppressed patients with rheumatic diseases. Clin Exp Rheumatol 2010; 28: 590-591.
7. Moltó A, Mateo L, Lloveras N, et al. Visceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with adalimumab. Joint Bone Spine 2010; 77: 271-273.
8. Kritikos K, Haritatos E, Tsigkos S, et al. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. J Clin Rheumatol 2010; 16: 38-39.
9. De Leonardis F, Govoni M, Lo Monaco A, Trotta F. Visceral leishmaniasis and anti-TNF-alpha therapy: case report and review of the literature. Clin Exp Rheumatol 2009; 27: 503-506.
10. Fabre S, Gibert C, Lechiche C, et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. Clin Exp Rheumatol 2005; 23: 891-892.
11. Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 2010; 362: 504-512.